Key Insights

Highlights

Treatment Research

18 treatments under study, led by Ilaprazole

Research Leaders

6 sponsors active, led by Shandong University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 4 (3)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT03571230Phase 4Unknown

Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

NCT03139253Phase 4UnknownPrimary

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

NCT02988089Phase 4Unknown

Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

Showing all 3 trials

Research Network

Common Treatments

  • Ilaprazole1
  • Tinidazole1
  • Amoxicillin And Furazolidone Or Amoxicillin And Tetracycline1
  • Amoxicillin1
  • Clarithromycin Susceptibility Dependant Strategy1

Active Sponsors

  • Shandong University2
  • General Hospital of Jinan Military Region1
  • Liaocheng People's Hospital1
  • Shandong Provincial Hospital1
  • Yanqing Li1

Top Investigators

Related Conditions

  • Helicobacter Pylori Infection2
  • Triple Therapy1

Activity Timeline